ストックスクリーナーアプリを入手
1.70
7.10%
-0.13
前日終値:
$1.83
開ける：
$1.77
24時間の取引高:
144.20K
Relative Volume:
0.09
時価総額：
$21.44M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-10.53%
1か月 パフォーマンス:
-43.71%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.69
$1.83
1週間の範囲:
$1.69
$2.0607
52週間の値動き範囲:
$1.60
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
名前
Propanc Biopharma Inc
セクター
電話
61-03-9882-0780
住所
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
PPCB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
4.34 | 6.18B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.12 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.825 | 133.49M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2646 | 577.51M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.085 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc (PPCB) 最新ニュース
Propanc Biopharma, Inc. SEC 10-K Report - TradingView
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads - The Globe and Mail
Reviewing Immatics (NASDAQ:IMTX) & Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc receives US patent for proenzyme cancer treatment composition By Investing.com - Investing.com South Africa
Propanc receives US patent for proenzyme cancer treatment composition - Investing.com
Propanc Biopharma Receives Certificate of Grant for 'Proenzyme Composition” Patent from US Patent & Trademark Office - The Manila Times
Propanc Biopharma Receives Certificate of Grant for - GlobeNewswire
$111.2B Market Opportunity: Propanc's Non-Toxic Cancer Drug PRP Receives Critical USPTO Patent - Stock Titan
Propanc Biopharma announces plan to acquire $100 million of Ethereum - MSN
Propanc to acquire $100M of Ethereum to accelerate pipeline - BioWorld MedTech
Propanc Biopharma’s $100M Ethereum Allocation: A Strategic Gamble or a Path to Growth? - AInvest
Propanc Biopharma, Inc. Announces $100 Million Ethereum Acquisition Plan to Enhance Growth and Diversification Strategy - Quiver Quantitative
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum - The Manila Times
$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy - Stock Titan
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Stem Cell Research - citybuzz -
D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq - AInvest
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Newswire.com
Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials - Investing.com
Propanc Biopharma shares fall 3.26% after-hours following shareholder update on corporate developments and Phase 1B study. - AInvest
Propanc Biopharma provides shareholder update - MarketScreener
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 By Investing.com - Investing.com South Africa
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 - Investing.com Nigeria
Propanc Biopharma Provides Shareholder Update - The Manila Times
Propanc Biopharma Announces Shareholder Update and 2025/26 Forecast. - AInvest
Propanc Biopharma: Recent IPO and Up-listing to Nasdaq, Advancing Lead Asset to Phase 1B Study - AInvest
$18.1B Market Potential: Propanc's Novel Cancer Drug PRP Heads to Human Trials After Successful Nasdaq IPO - Stock Titan
Propanc Biopharma Completes Public Offering on Nasdaq - MSN
Propanc Biopharma opens at $4.00 in Nasdaq uplisting - MSN
Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect - The Globe and Mail
PPCB: Is Recent Nasdaq Uplisting a Game-Changer? - StocksToTrade
Propanc Biopharma’s Surging Market Debut: What’s Next? - timothysykes.com
Stocks Moving Premarket: NBY, AUDD, PPCB And Other Gainers & Losers - RTTNews
Propanc Biopharma shares rise 34.88% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma Stock Soars 51.23% on Capital Raise - AInvest
Propanc Biopharma shares rise 61.58% premarket after closing a $4 million public offering. - AInvest
Why Did Propanc Biopharma Stock Soar 27.25%? - AInvest
Propanc Biopharma Announces Nasdaq Uplisting, $4M Public Offering - AInvest
Propanc Biopharma shares rise 19.89% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma shares rise 21.20% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma Raises $4M Through Public Offering, Begins Trading on NASDAQ - AInvest
Propanc Biopharma's NASDAQ Uplisting: A Strategic Leap in Immuno-Oncology's High-Stakes Arena - AInvest
Propanc Biopharma closes $4 million public offering, lists on Nasdaq - Investing.com
Propanc Biopharma closes $4 million public offering, lists on Nasdaq By Investing.com - Investing.com UK
Propanc Biopharma raises $4 million in underwritten public offering. - AInvest
Propanc Biopharma Completes Public Offering, Uplisted to NASDAQ - AInvest
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ - MarketScreener
Cancer Treatment Developer Propanc Biopharma Raises $4M in IPO, Achieves Major Nasdaq Uplisting Milestone - Stock Titan
Propanc Biopharma Plunges 15.04% Amid Tariff Fears - AInvest
Why Propanc stock Is Tumbling In Premarket Today - Asianet Newsable
Propanc Biopharma Inc (PPCB) 財務データ
Propanc Biopharma Inc (PPCB) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):